EPOR and neoplasm: To support the lack of Epo driven pathway activation observed in disaggregated tumor samples, cell-surface EpoR was also analyzed in disaggregated, live tumor cells from the cohort of 186 patients (Table 1) by flow cytometry using the specific anti-EpoR antibody MAb307.